Behavioral Therapy for Eating Disorders in Children & Adolescents | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone offer cognitive behavioral therapy to treat children with some eating disorders.
Behavioral Therapy for Mood Disorders in Children | NYU Langone Health
Experts at the Child Study Center, part of Hassenfeld Children’s Hospital at NYU Langone, offer cognitive behavioral therapy for mood disorders.
Behavioral Treatments for Sleep Disorders in Children | NYU Langone Health
Sleep specialists at Hassenfeld Children’s Hospital at NYU Langone offer behavioral strategies to improve sleep in infants and children.
Behcet’s Disease | NYU Langone Health
NYU Langone rheumatologists provide care for people with this rare immune system disorder.
Behcet’s Disease Recovery & Support | NYU Langone Health
NYU Langone rheumatologists offer care over the long term for people with Behçet’s disease.
Benign Vocal Cord Lesions | NYU Langone Health
Voice specialists at NYU Langone offer expert diagnosis and treatment of benign vocal cord lesions using new technologies, procedures, and voice therapy.
Better health starts with a better health system. | NYU Langone Health
At NYU Langone Health, we believe that better health starts with a better health system.
bhng 0A Phase 1/2 Open-label Study to Investigate the Safety Efficacy and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
This is a multicenter, single arm, open-label, combined 2-part phase 1/2 dose escalation and expansion study in adult subjects with R/R B-ALL, evaluating the safety, tolerability, pharmacokinetic (PK), and efficacy of SC blinatumomab as monotherapy. The first part (phase 1 [Ph1]) is a dose-finding study to investigate the PK, safety, and clinical activity of escalating dose levels of SC blinatumomab in adults (age ? 18 years) with R/R B-ALL. Once a recommended dose has been selected in the phase 1 (Ph 1) part of the study, the phase 2 (Ph2) part will begin to assess the safety and efficacy of the recommended dose level of SC blinatumomab in adults.The study will evaluate SC administration of blinatumomab as a potentially moreconvenient mode of administration and explore higher doses in the dose escalation(Ph1) part of the study and will be conducted at approximately 40 sites. The study willconsist of up to a 3-week screening and pre-phase period, a treatment period, a safetyfollow-up visit 30 (? 3) days after last dose of study treatment, and a long-term follow-up period (for Ph2 only) lasting approximately 2 years after the first dose of investigational product (IP) is received.
Bile Duct Cancer | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, our experts diagnose and treat bile duct cancer and other liver conditions.
Biliary Atresia in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat babies with biliary atresia, which causes blockages in bile ducts.